Hosted on MSN1mon
Reducing dose of popular blood thinners may limit risk of future bleeding, study findsThe research team focused the study on the two most prescribed direct oral anticoagulants, or DOACs, rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis). Investigators analyzed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback